{"preliminary_commentary":{"by_channel":{"x_thread":7,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03177382\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[],"indication":"high-risk locally advanced rectal cancer","name":"TNTCRT","nct_id":"NCT03177382","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tntcrt-nct03177382. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TNTCRT","arms":[{"description":"The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w. The TME operation will be given 3-4 weeks after the end of the total neoadjuvant treatment.","label":"Total neoadjuvant treatment","type":"EXPERIMENTAL"},{"description":"The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.","label":"concurrent chemoradiotherapy group","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2023-05-30","type":"ESTIMATED"},"conditions":["Total Neoadjuvant Treatment","Chemoradiotherapy","Local Advanced Rectal Cancer","High Risk Factors"],"enrollment":{"count":458,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Total neoadjuvant treatment","otherNames":["TNT"],"type":"RADIATION"},{"name":"concurrent chemoradiotherapy","otherNames":["CRT"],"type":"RADIATION"},{"name":"TME","otherNames":[],"type":"PROCEDURE"},{"name":"Adjuvant chemotherapy","otherNames":[],"type":"DRUG"}],"last_update":"2018-05-08","lead_sponsor":"West China Hospital","official_title":"Total Neoadjuvant Treatment Versus Conventional Neo-chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk Factors: a Multicenter Randomized Phase III Clinical Study.","overall_status":"UNKNOWN","phases":["PHASE3"],"primary_completion_date":{"date":"2021-05-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"disease free survival","timeFrame":"3 years"}],"references":[{"citation":"Wang X, Tang Y, Lu J, Meng W, Liu P, Zhou J, Wen F, Ding P, Li J, Wang B, Guo Q, Qiu J, Sun H, Deng X, Shen Y, Zeng H, Jiang D, Wang D, Li Y, Xiao Y, Wang Z. Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial. J Clin Oncol. 2026 Jul 23:JCO2503110. doi: 10.1200/JCO-25-03110. Online ahead of print.","pmid":"42492015","type":"DERIVED"}],"start_date":{"date":"2017-06-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors","url":"https://clinicaltrials.gov/study/NCT03177382"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tntcrt-nct03177382"}